Related Experiment Video

Updated: Aug 9, 2026

Paired Cisterna Magna Nanoinjection and Laser Speckle Contrast Imaging Assay to Study Cerebral Blood Flow Regulation In Vivo
06:24

Paired Cisterna Magna Nanoinjection and Laser Speckle Contrast Imaging Assay to Study Cerebral Blood Flow Regulation In Vivo

Published on: July 8, 2025

Cholinergically mediated augmentation of cerebral perfusion in Alzheimer's disease and related cognitive disorders:

Jurgen A H R Claassen1, René W M M Jansen

  • 1Department of Geriatric Medicine, Radboud University Medical Center, PO Box 9101, 6500 HB Nijmegen, The Netherlands. j.claassen@ger.umcn.nl

The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences
|March 29, 2006
PubMed

Insights

Cholinesterase inhibitors may treat Alzheimer's disease (AD) by improving blood flow to the brain, not just by boosting acetylcholine. This cholinergic-vascular hypothesis offers a new perspective on AD treatment strategies.

Area of Science:

  • Neuroscience
  • Pharmacology
  • Vascular Biology

Background:

  • Current Alzheimer's disease (AD) treatment relies on the cholinergic hypothesis, focusing on acetylcholine levels.
  • This hypothesis inadequately explains the widespread effects and variable responses observed with cholinesterase inhibitors (ChEIs).
  • Existing models do not fully account for ChEI efficacy across different dementias or significant individual response variations.

Purpose of the Study:

  • To propose and review evidence for the cholinergic-vascular hypothesis of AD treatment.
  • To explore the role of the cholinergic system in regulating cerebral perfusion and neurovascular function.
  • To discuss the implications of this hypothesis for AD treatment strategies and its interaction with other AD hypotheses.

Main Methods:

  • Review of preclinical and clinical research investigating the cholinergic system's vascular functions.
  • Analysis of existing data on cholinesterase inhibitor effects in Alzheimer's disease and other dementias.
  • Theoretical integration of the cholinergic-vascular hypothesis with vascular and amyloid hypotheses of AD.

Main Results:

  • Evidence suggests cholinesterase inhibitors may primarily enhance cerebral perfusion.
  • The cholinergic system plays a significant role in neurovascular regulation and functional hyperemia.
  • Intraindividual variability in ChEI response may be linked to vascular factors.

Conclusions:

  • The cholinergic-vascular hypothesis offers a more comprehensive explanation for ChEI effects in Alzheimer's disease.
  • Cholinergic deficits in AD contribute to neurovascular dysfunction, impacting disease pathology and clinical symptoms.
  • This revised understanding necessitates exploring novel therapeutic strategies targeting neurovascular mechanisms in AD.

More Related Videos

Placement of Extracranial Stimulating Electrodes and Measurement of Cerebral Blood Flow and Intracranial Electrical Fields in Anesthetized Mice06:34

Placement of Extracranial Stimulating Electrodes and Measurement of Cerebral Blood Flow and Intracranial Electrical Fields in Anesthetized Mice

Published on: June 2, 2023

Related Concept Videos

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists01:30

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function. They...
Dementia l: Introduction01:22

Dementia l: Introduction

Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Indirect-Acting Cholinergic Agonists: Pharmacological Actions01:30

Indirect-Acting Cholinergic Agonists: Pharmacological Actions

Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Direct-Acting Cholinergic Agonists: Pharmacological Actions00:59

Direct-Acting Cholinergic Agonists: Pharmacological Actions

Direct-acting cholinergic agonists exert their pharmacological actions by mimicking the effects of acetylcholine on postsynaptic muscarinic receptors to generate parasympathetic responses. These agents elicit a range of physiological responses, including cardiovascular effects. For example, activation of muscarinic receptors induces bradycardia, decreased cardiac output, reduced peripheral resistance, and consequent hypotension. In the eye, stimulation of M3 receptors leads to smooth muscle...